$227.83
N/A
Ult. Agg.: Sep 30, 4:27 PM
$227.83
N/A
Ascendis Pharma (ASND) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ascendis Pharma (ASND) ha pubblicato l'ultima guidance il gennaio 9, 2026 per fiscal year 2025. La società ha previsto un fatturato pari a $838.19M - $838.19M per il periodo.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.78 | $0.21 | $-0.06 | $-0.41 |
| Actual | $1.05 | $0.32 | $-0.64 | $-1.17 |
| Surprise | +34.6% | +52.4% | -966.7% | -185.1% |
| Revenue | ||||
| Estimate | $353.8M | $318.1M | $289.7M | $248.6M |
| Actual | $394.4M | $288.8M | $288.1M | $249.8M |
| Surprise | +11.5% | -9.21% | -0.55% | +0.46% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.13 | $1.41 | $1.45 | $2.00 |
| Revenue | ||||
| Consensus | $420.1M | $466.6M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $1.05 | $0.78 | 34.6 % |
| Q1 | May 7, 2026 | $0.32 | $0.21 | 52.4 % |
| Q4 | Feb 11, 2026 | $-0.64 | $-0.06 | -966.7 % |
| Q3 | Nov 12, 2025 | $-1.17 | $-0.41 | -185.1 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $394.44M | $353.80M | 11.5 % |
| Q1 | May 7, 2026 | $288.77M | $318.05M | -9.21 % |
| Q4 | Feb 11, 2026 | $288.13M | $289.72M | -0.55 % |
| Q3 | Nov 12, 2025 | $249.79M | $248.64M | 0.46 % |